Elaine J Abrams1, Selamawit Woldesenbet, Juliana Soares Silva, Ashraf Coovadia, Viviane Black, Karl-Günter Technau, Louise Kuhn. 1. From the *ICAP, Mailman School of Public Health, †Department of Epidemiology, Mailman School of Public Health, and ‡Department of Pediatrics, College of Physicians & Surgeons, Columbia University, New York, New York; §Empilweni Services and Research Unit, Department of Pediatrics and Child Health, Rahima Moosa Mother and Child Hospital, and ¶Department of Clinical Microbiology and Infectious Diseases, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa; and ‖Sergeivsky Center, College of Physicians & Surgeons, Columbia University, New York, New York.
Abstract
BACKGROUND: Outcomes of HIV-infected children before widespread use of antiretroviral therapy (ART) for treatment and prevention of mother-to-child transmission (PMTCT) have been well characterized but less is known about children who acquire HIV infection in the context of good ART access. METHODS: We enrolled newly diagnosed HIV-infected children ≤24 months of age at 3 hospitals and 2 clinics in Johannesburg, South Africa. We report ART initiation and mortality rates during 6 months from enrollment and factors associated with mortality. RESULTS: Of 272 children enrolled, median age 6.1 months, 69.5% were diagnosed during hospitalization. By 6 months postenrollment, 53 (19.5%) died and 73 (26.8%) were lost-to-follow-up. Using Kaplan-Meier analysis, the probability of death by 6 months after enrollment was 23.5%. The median age of death was 9.1 months [95% confidence interval (CI): 8.6-12.0]. Overall, 226 (83%) children initiated ART which was associated with a 71% reduction in risk of death [hazard ratio (HR) = 0.29 (95% CI: 0.15-0.58)]. In multivariable analysis of infant factors, weight-for-age Z score < -2 standard deviation (SD) [HR = 2.43 (95% CI: 1.03-5.73)], CD4 <20% [HR = 3.29 (95% CI: 1.60-6.76)] and identification during hospitalization [HR = 2.89 (95% CI: 1.16-7.25)] were independently associated with mortality. In multivariable analysis of maternal factors, CD4 ≤350/no maternal ART was associated with increased mortality risk [HR = 2.57 (95% CI: 1.19-5.59)] versus CD4 >350/no maternal ART; exposure to maternal/infant antiretrovirals for PMTCT was associated with reduced mortality risk [HR = 0.53 (95% CI: 0.28-0.99)] versus no PMTCT. CONCLUSIONS: ART initiation is highly protective against death in young children. However, despite improved access to ART, young children remain at risk for early death; innovative approaches to rapidly diagnose and initiate treatment as early in life as possible are needed.
BACKGROUND: Outcomes of HIV-infectedchildren before widespread use of antiretroviral therapy (ART) for treatment and prevention of mother-to-child transmission (PMTCT) have been well characterized but less is known about children who acquire HIV infection in the context of good ART access. METHODS: We enrolled newly diagnosed HIV-infectedchildren ≤24 months of age at 3 hospitals and 2 clinics in Johannesburg, South Africa. We report ART initiation and mortality rates during 6 months from enrollment and factors associated with mortality. RESULTS: Of 272 children enrolled, median age 6.1 months, 69.5% were diagnosed during hospitalization. By 6 months postenrollment, 53 (19.5%) died and 73 (26.8%) were lost-to-follow-up. Using Kaplan-Meier analysis, the probability of death by 6 months after enrollment was 23.5%. The median age of death was 9.1 months [95% confidence interval (CI): 8.6-12.0]. Overall, 226 (83%) children initiated ART which was associated with a 71% reduction in risk of death [hazard ratio (HR) = 0.29 (95% CI: 0.15-0.58)]. In multivariable analysis of infant factors, weight-for-age Z score < -2 standard deviation (SD) [HR = 2.43 (95% CI: 1.03-5.73)], CD4 <20% [HR = 3.29 (95% CI: 1.60-6.76)] and identification during hospitalization [HR = 2.89 (95% CI: 1.16-7.25)] were independently associated with mortality. In multivariable analysis of maternal factors, CD4 ≤350/no maternal ART was associated with increased mortality risk [HR = 2.57 (95% CI: 1.19-5.59)] versus CD4 >350/no maternal ART; exposure to maternal/infant antiretrovirals for PMTCT was associated with reduced mortality risk [HR = 0.53 (95% CI: 0.28-0.99)] versus no PMTCT. CONCLUSIONS:ART initiation is highly protective against death in young children. However, despite improved access to ART, young children remain at risk for early death; innovative approaches to rapidly diagnose and initiate treatment as early in life as possible are needed.
Authors: P M Garcia; L A Kalish; J Pitt; H Minkoff; T C Quinn; S K Burchett; J Kornegay; B Jackson; J Moye; C Hanson; C Zorrilla; J F Lew Journal: N Engl J Med Date: 1999-08-05 Impact factor: 91.245
Authors: Louise Kuhn; Grace M Aldrovandi; Moses Sinkala; Chipepo Kankasa; Mwiya Mwiya; Donald M Thea Journal: AIDS Date: 2010-06-01 Impact factor: 4.177
Authors: Elaine J Abrams; Jeffrey Wiener; Rosalind Carter; Louise Kuhn; Paul Palumbo; Stephen Nesheim; Francis Lee; Peter Vink; Marc Bulterys Journal: AIDS Date: 2003-04-11 Impact factor: 4.177
Authors: Anisa Ghadrshenas; Yanis Ben Amor; Joy Chang; Helen Dale; Gayle Sherman; Lara Vojnov; Paul Young; Ram Yogev Journal: AIDS Date: 2013-11 Impact factor: 4.177
Authors: Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre Journal: N Engl J Med Date: 2008-11-20 Impact factor: 91.245
Authors: Mary-Ann Davies; Margaret May; Carolyn Bolton-Moore; Cleophas Chimbetete; Brian Eley; Daniela Garone; Janet Giddy; Harry Moultrie; James Ndirangu; Sam Phiri; Helena Rabie; Karl-Günter Technau; Robin Wood; Andrew Boulle; Matthias Egger; Olivia Keiser Journal: Pediatr Infect Dis J Date: 2014-06 Impact factor: 2.129
Authors: Shaffiq Essajee; Lara Vojnov; Martina Penazzato; Ilesh Jani; George K Siberry; Susan A Fiscus; Jessica Markby Journal: J Int AIDS Soc Date: 2015-12-02 Impact factor: 5.396
Authors: Victoria Iyun; Karl-Gunter Technau; Brian Eley; Helena Rabie; Andrew Boulle; Geoffrey Fatti; Matthias Egger; Frank Tanser; Robin Wood; Lee Fairlie; Mark F Cotton; Mary-Ann Davies Journal: Pediatr Infect Dis J Date: 2020-02 Impact factor: 3.806
Authors: Victoria Iyun; Karl-Gunter Technau; Michael Vinikoor; Marcel Yotebieng; Rachel Vreeman; Lisa Abuogi; Sophie Desmonde; Andrew Edmonds; Madeleine Amorissani-Folquet; Mary-Ann Davies Journal: Lancet HIV Date: 2021-04-28 Impact factor: 16.070
Authors: Jane R Millar; Isabella Fatti; Noxolo Mchunu; Nomonde Bengu; Nicholas E Grayson; Emily Adland; David Bonsall; Moherndran Archary; Philippa C Matthews; Thumbi Ndung'u; Philip Goulder Journal: AIDS Date: 2021-08-01 Impact factor: 4.632
Authors: Jane R Millar; Nomonde Bengu; Rowena Fillis; Ken Sprenger; Vuyokazi Ntlantsana; Vinicius A Vieira; Nisreen Khambati; Moherndran Archary; Maximilian Muenchhoff; Andreas Groll; Nicholas Grayson; John Adamson; Katya Govender; Krista Dong; Photini Kiepiela; Bruce D Walker; David Bonsall; Thomas Connor; Matthew J Bull; Nelisiwe Nxele; Julia Roider; Nasreen Ismail; Emily Adland; Maria C Puertas; Javier Martinez-Picado; Philippa C Matthews; Thumbi Ndung'u; Philip Goulder Journal: EClinicalMedicine Date: 2020-05-08